Company profile

In Silico

In Silico, founded in 2014 and headquartered in Cambridge, Massachusetts, raised $110 million in a Series E funding round in January 2025, bringing total funding to $510 million from investors including eBridge Ventures and Deerfield. The platform provides AI-enabled bioinformatics solutions for drug discovery, biomarker development, and aging research. Its PHARMA.AI product suite, including PandaOmics, Chemistry42, and InClinico, accelerates therapeutic development and clinical research. With strong funding and AI capabilities, In Silico is positioned to advance genomics and life sciences innovation globally.

Back to profiles

Quick facts

Total funding: $110 million
Founded: 2014
Headquarters: Cambridge, Massachusetts

Notable investors

Deerfield

Reach buyers like In Silico on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like In Silico
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like In Silico.

The 14-day trial ships every feature, no card required.

Start free →